Sept 5 (Reuters) - Intellipharmaceutics International Inc IPCI.TO :
* Intellipharmaceutics provides operational update
* Currently anticipate Rexista program study will take nine months from commencement to complete
* Is in process of commencing its planned Category 3 study to support certain label claims for Rexista(TM)
* Trial date for previously announced patent litigation by Purdue against co regarding Rexista(TM) set for Oct 22, 2018
* FDA is stayed from granting approval of Rexista until August 24, 2019